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Abstract  
We assessed internal consistency,   validity, reliability and agreement of MSQoL-29  ; a 
shorter version of MSQoL-54 used for assessing Quality of life of people with Multiple 
sclerosis.  
100 participants were recruited and 91 completed the study.   Internal consistency of 
MSQOoL-29 was good . Intraclass correlation coefficients were strongly positive between  
MSQoL -54 and MSQoL -29  and between the  MSQoL-29  done 4 to 8 weeks apart . On 
Bland-Altman plots, the MSQoL-29 scores of 95% of participants done 4 to 8 weeks 
apart were within the limits of agreement. Time to complete MSQoL-29 was 12.5 
minutes shorter than for MSQOL-54 . 
MSQoL-29 has good internal consistency, validity and test-retest reliability and was 
quicker to complete.  
  
 Introduction: 
Persons with multiple sclerosis (PwMS) have lower Health Related Quality of Lofe (HRQoL) 
compared to people living with  long term conditions like Parkinson’s disease, epilepsy 
and diabetes mellitus2,3.  4. MSQoL-54 is a MS-specific HRQoL instrument  validated in 
many languages 5.   Based on responses for each of the 54 questions, the scores are 
linearly transformed into two composite scores, the Physical Health Composite (PHC) and 
Mental Health Composite (MHC);the values of each range from 0 to 100, with higher 
scores indicative of a higher HRQoL6. Using confirmatory factor analysis and Rasch 
modelling Rosato et al  devised a shortened version with 29 questions called MSQoL-297.  
The aim of this study is to assess the validity, reliability, internal consistency and 
acceptability of MSQoL-29 in an English speaking cohort. 
Participants and methods 
We conducted this study at a regional MS centre in United Kingdom. The study received 
ethical approval from the York Research Ethics Committee.  Inclusion criteria were 1) 
diagnosis of MS according to the 2010 revision of McDonald’s criteria 8 2) ability to read 
and understand written English, 3) consent to participate in the trial, 4) able to attend 
two appointments 4 to 8 weeks apart. Patients with cognitive issues that would impair 
understanding of the questionnaires were excluded from the trial.  
At initial visit the participants completed both MSQoL-54 and MSQoL-29and a feedback 
form. The order of administration of the two questionnaires was randomised (online 
random number generator) so that half of the participants   completed the MSQoL-29 
first and the others completed the MSQoL-54 first. The time taken to complete the 
questionnaires was recorded. After 4 to 8 weeks participants with relapses or significant 
health problems requiring hospitalisation or an appointment with doctor were excluded. 
Others completed MSQoL-29. .   
Statistical analyses: Statistical analyses were performed using SPSS version 22.0 for 
Windows and version 23.0 for Macintosh. All tests were two sided and significance was 
accepted at 5% (α=0.05). Internal consistency was assessed using Cronbach’s alpha 9 . 
Intraclass Correlation Coefficients (ICC) were used to assess the validity of MSQoL-29 by 
looking at its correlations with MSQoL-54. The test retest reliability was assessed 
calculating ICC between MSQoL-29 administered 4-8 weeks apart 10.  Bland-Altman plots 
were used to assess the agreement between MSQoL 54 and 29 .12,13   The limits of 
agreement (LOAs) were taken as 2 SD of the mean of MSQoL 29 and 54 13.  The 
agreement between  the two MSQoL-29 scores were also assessed using Bland-Altman 
plots and limits of agreement (LOAs) were taken as 2 SD of the mean of MSQoL 29 for 
visits 1 and 2 .Feedback responses were analysed as frequencies.  
Results: 
A total of 100 participants were recruited and 91 completed both visits. Socio-
demographic and clinical characteristics of participants are shown in Table 1.  
Table 1: Sociodemographic and clinical characteristics of the participants 
 None of the patients scored minimum or maximum in PHC or MHC during any of the 
assessments. The mean time to complete MSQoL-54 was 19.79 +6.93 minutes and 
MSQoL-29 was 7.22 +2.94 minutes. Participants took 12.5 minutes less to complete 
MSQoL-29. (paired t test t=-12.148, p= 0.0001). The Cronbach’s alpha for MSQoL-29 
PHC was 0.875 and MSQoL-29 MHC was 0.914 suggestive of good internal consistency10.  
The ICC between MSQoL 54 and MSQoL-29 were : PHC-0.914 (CI  0.872 – 0.942), MHC- 
0.875 (CI- 0.814 to 0.916). The ICC between two MSQoL-29 scores done 4 to 8 weeks 
apart were: PHC- 0.970 , CI-  0.955 -0.980 and MHC - 0.937, CI- 0.904 -0.958.   
  The Bland Altman plots of agreement for MHC and PHC scores of MSQoL-54 and 
MSQoL-29 and two MSQoL-29 scores showed that that 95% of observations were 
between the LOA.  
   
 
  
4 
Of the 91 participants 51(52.6% ) indicated they had no preference between MSQoL-54 
and MSQoL-29 and 40( 47.4%0 preferred MSQoL-29. The participants found MSQoL-54 
‘long’, or ‘time consuming’ . Two participants were concerned about removal of the 
bladder and bowel dysfunction question in MSQoL-29. Three participants did not like the 
questions regarding sexual function, . 
Discussion 
The study evaluated the internal consistency, validity and reliability of MSQoL-29 for the 
first time in an English speaking cohort of PwMS.  The feedback from the participants 
indicated that MSQoL-29 was an acceptable tool.  Our data show that MSQoL is preferred 
by the patient and is quicker to complete than MSQoL-54.  
The internal consistency of MSQoL-29 for both PHC and MHC was excellent and good 
respectively.  .14-16 As observed by Rosato et al. in the Italian speaking population, we 
noted a strong correlation between scores of MSQoL-54 and MSQoL-29. 8 Our data 
showed that reliability of MSQoL-29 is as good as that of MSQoL-54 7,15.The MSQoL-29 is 
as valid and reliable a tool to evaluate QoL in PwMS as MSQoL-54.  
, When two different methods are measuring the same outcome, it is expected that there 
would be a moderate correlation based on the simple fact that the outcome being 
measured is the same. Bland-Altman plot is a more thorough method of analysis, where 
results from individual participants can be scrutinised. 12,13   In the Bland-Altman plot, the  
overall agreement between MSQoL 54 and MSQoL-29 and MSQoL-29 done 4-8 weeks 
apart  appears good. There is considerable variation between scores in certain   
participants.  There are no studies on any HRQoL instruments using Bland-Altman plot.  
Further studies are required to ascertain whether wide limits of agreement are likely to 
be clinically relevant. 
Both MSQoL 54 and MSQoL-29 did not show ceiling or floor effect. Differences in the 
mean time to complete the two instruments were  significantly shorter for MSQoL-29.  
Ten minutes has been cited as the length of time fully compatible with clinical practice .18 
The mean time required to complete MSQoL-29 was 7.22 +2.94 minutes;12.5 minutes 
less than the time to complete MSQoL-54.  In view of the comparable validity and 
reliability and shorter completion time MSQoL-29 would likely be  more appropriate tool 
in clinical practice .  
Limitations 
Almost all  participants had RRMS and EDSS score of 4.5 to 7.0. Future research on 
MSQoL-29 need to include a more diverse sample of PwMS. The MSQoL- 29 was not 
validated against any other QoL measures.    
Conclusion 
Ours was the first study to investigate the validity and reliability of MSQoL-29 in a large 
English speaking cohort. This study showed that MSQoL-29 is an internally consistent, 
valid and reliable instrument to measure QoL in PwMS. It could be completed at less 
than 10 minutes. Further research evaluating the Bland-Altman agreement of HRQoL 
instruments is required.  
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Table 1: Sociodemographic and clinical characteristics of the participants 
 
 Variables  
Age, mean years  42.8 ( SD- 
9.179, range- 
20 -67)  
Gender 
Men 
Women 
 
30 
70 
Education 
School 
Vocationally trained 
University 
 
40 
18 
42 
 
Living arrangements 
Alone 
With partner, family or 
carer 
 
32 
78 
Care needs 
Nil 
Requires assistance 
 
54 
46 
Type of MS 
Relapsing-remitting 
Secondary progressive 
 
98 
2 
Duration since MS 
diagnosis, mean years  
5.5 ( SD- 
7.15, Range- 
0.5 -30)) 
EDSS score 
4.5 
5.0 
5.5 
6.0 
6.5 
7 
 
32 
13 
4 
31 
11 
9 
 
